Significance Statement {#s104}
======================

It has been documented that dopamine D2 receptors exist in 2 distinct states with high and low affinities for endogenous dopamine. Here, we quantified total and high-affinity-state D2 receptors in the striatal subregions of healthy controls and patients with schizophrenia by PET with a D2-type receptor antagonist, \[^11^C\]raclopride, and a D2-type receptor agonist, \[^11^C\]MNPA, respectively, and demonstrated a higher proportion of the high-affinity state of D2 receptors in the putamen of the patients. Additionally, the binding of these 2 radioligands in the caudate of the patients was positively correlated with their scores of Positive and Negative Syndrome Scale (PANSS) "depressed" factor. These findings support the utility of PET with a D2-type receptor antagonist and a D2-type receptor agonist in the same individual for investigating a change in the total amount or affinity state of this receptor as a possible molecular basis of symptomatic manifestations in schizophrenia.

Introduction {#s1}
============

Dysregulation in dopamine neurotransmission is thought to underlie the pathophysiology of schizophrenia ([@CIT0021]; [@CIT0005]). This concept has been supported for decades by evidence that the clinical effect of antipsychotics is mediated by dopamine D2 receptor (D2R) blockade ([@CIT0026]).

Previous in vitro studies have suggested that D2R has 2 interconvertible affinity states for endogenous dopamine, referred to as G-protein-coupled high-affinity (D2^High^) and G-protein-uncoupled low-affinity (D2^Low^) states ([@CIT0006]; [@CIT0037]; [@CIT0012]; [@CIT0028]). D2^High^ is a functionally active state of D2R ([@CIT0012]). Elevations of D2^High^ have been reported in several different animal models of schizophrenia, and it has been suggested that an increased proportion of D2^High^ might play an important role in the pathophysiology of schizophrenia ([@CIT0032]; [@CIT0030]).

\[^11^C\]raclopride is a widely used D2R ligand for visualizing this receptor in the brains of living subjects by positron emission tomography (PET). While \[^11^C\]raclopride is a D2-type receptor antagonist with similar affinities for D2^High^ and D2^Low^ ([@CIT0035]), the D2-type receptor agonists, exemplified by (-)-N-\[^11^C\]propyl-norapomorphine (\[^11^C\]NPA) ([@CIT0016]), \[^11^\]C(+)-4-propyl-3,4,4a,5,6,10b-hexahydro-2H-naphtho\[1,2-b\]\[1,4\]oxazin-9-ol (\[^11^C\]PHNO) ([@CIT0045]), and \[^11^C\](R)-2-CH3O-N-n-propylnorapomorphine (\[^11^C\]MNPA) ([@CIT0008]), have been shown to have a higher affinity for D2^High^ than D2^Low^ ([@CIT0037]; [@CIT0035]; [@CIT0044]; [@CIT0036]; [@CIT0011]).

Only a limited number of clinical studies have hitherto investigated D2^High^ availability in patients with schizophrenia in vivo, and whether there are alterations in the ligand binding to D2^High^ or in the proportion of D2^High^ in patients with schizophrenia still remains a question. Previous PET studies using \[^11^C\]PHNO have shown that there were no significant changes in its binding potential in patients with schizophrenia compared with healthy controls ([@CIT0013]; [@CIT0040]). However, \[^11^C\]PHNO was reported to have a 50-fold higher affinity for dopamine D3 receptor (D3R) than D2R ([@CIT0010]; [@CIT0025]), potentially hampering sensitive detection of D2^High^. In contrast to \[^11^C\]PHNO, \[^11^C\]MNPA has almost identical affinities for D2R and D3R, with dissociation constant (Kd) values of 2.21 nM and 2.02 nM, respectively ([@CIT0038]), and thus might be more suitable for assessing D2^High^ ([@CIT0018]). In addition, the binding potential ratio between the 2 ligands, \[^11^C\]raclopride and \[^11^C\]MNPA, could be a possible index of the proportion of D2^High^ vs total D2Rs, as indicated in a previous study for healthy subjects ([@CIT0018]).

In this study, we aimed to investigate the availability of D2^High^ in antipsychotic-free patients with schizophrenia using PET with both antagonist and agonist ligands.

Methods {#s2}
=======

Participants {#s3}
------------

A total of 11 patients with schizophrenia (4 men and 7 women) were recruited from affiliated hospitals or clinics. Seventeen healthy controls (8 men and 9 women) were recruited by the National Institute of Radiological Sciences, Chiba, Japan, for participation in this study.

The patient group was comprised of 10 antipsychotic-naive patients (one had taken benzodiazepines the night before her PET scans) and 1 patient who had been antipsychotic-free for 2 years after 1-year treatment with aripiprazole. All patients fulfilled the diagnostic criteria for schizophrenia according to DSM-IV. None of the patients were comorbid with other neuropsychiatric disorders or had substance abuse. Psychopathology was assessed using the Positive and Negative Syndrome Scale (PANSS) ([@CIT0017]), and a 5-factor model ([@CIT0043]) was used to calculate PANSS subscale scores (positive, negative, disorganized/concrete, excited, and depressed factors). The healthy control volunteers were recruited by public notices. They had no history of psychiatric disease, neurological injury or disease, severe medical diseases, substance abuse that may affect brain functions, or first-degree relatives suffering from psychotic episodes. All the diagnostic interviews and PANSS ratings were conducted by trained psychiatrists. [Table 1](#T1){ref-type="table"} presents the participants' demographic information.

###### 

Demographic and Clinical Characteristics of Subjects

                                                             Patient group (n=11)   Control group (n=17)   Statistics   *P*             
  ---------------------------------------------------------- ---------------------- ---------------------- ------------ ------- ------- -----
  Age (y)                                                    33.9                   6.5                    33.8         9.6     0.047   .96
  Gender (male/female)                                       4/7                                           8/9                          .71
  Smoker (yes/no)                                            4/7                                           4/13                         .67
  Injected radioactivity of \[^11^C\]raclopride (MBq)        224.8                  14.4                   221.5        15.3    -0.57   .58
  Injected radioactivity of \[^11^C\]MNPA (MBq)              220.1                  17.9                   221.2        16.3    -0.17   .87
  Specific radioactivity of \[^11^C\]raclopride (GBq/mmol)   178.1                  87.6                   206.2        140.0   -0.65   .52
  Specific radioactivity of \[^11^C\]MNPA (GBq/mmol)         173.3                  99.5                   182.5        166.0   -0.17   .87
  Age at onset (y)                                           31.1                   5.5                                                 
  Duration of illness (y)                                    3.3                    4.3                                                 
  PANSS total score                                          77.6                   22.5                                                
  PANSS factor                                                                                                                          
   Positive                                                  13.5                   3.0                                                 
   Negative                                                  12.4                   5.5                                                 
   Disorganized/concrete                                     7.3                    2.6                                                 
   Excited                                                   8.5                    3.5                                                 
   Depressed                                                 8.4                    3.0                                                 

This study was approved by the Radiation Drug Safety Committee and the Institutional Review Board of the National Institute of Radiological Sciences, Japan, and was carried out in accordance with the Code of Ethics of the World Medical Association. After complete description of the study, written informed consent was obtained from all participants. Data were collected between April 2008 and October 2016.

PET Procedures {#s4}
==============

All subjects underwent 2 PET scans on the same day, one with \[^11^C\]raclopride and the other with \[^11^C\]MNPA, except 1 control subject who took the 2 scans on separate days due to technical trouble. \[^11^C\]MNPA-PET preceded \[^11^C\]raclopride-PET in 10 patients and 11 controls, and \[^11^C\]raclopride-PET was followed by \[^11^C\]MNPA-PET in 1 patient and 6 controls. After i.v. rapid bolus injection of \[^11^C\]raclopride, a PET scan was performed for 60 minutes. Similarly, after i.v. rapid bolus injection of \[^11^C\]MNPA, a PET scan was performed for 90 minutes. The time interval between initiations of the first and second PET scans was 120 minutes or longer. For both PET scans, 3-dimensional dynamic PET data were acquired with a Siemens ECAT Exact HR+ system (CTI/Siemens), which provides 63 sections with an axial field of view of 15.5 cm. PET images were reconstructed with a filtered back-projection method with corrections for attenuation and scatter. The reconstructed in-plane resolution was 7.5 mm full-width at half-maximum. A 10-minute transmission scan using a ^68^Ge/^68^Ga line source was performed before each PET scan for attenuation correction. A thermoplastic head fixation device was used to minimize head movement during PET scanning. The dynamic scans consisted of twelve 20-second frames, sixteen 60-second frames, and ten 240-second frames for \[^11^C\]raclopride, and nine 20-second frames, five 60-second frames, four 120-second frames, eleven 240-second frames, and six 300-second frames for \[^11^C\]MNPA.

MRI Procedures {#s5}
--------------

Because of replacements of MRI machines during this study, 3 types of MRI devices were used depending on the time of participant recruitment. For the initial 4 patients and 7 controls, MR images were acquired with a 1.5-T MR scanner (Intera, Philips Medical Systems). 3D volumetric acquisition of a T1-weighted gradient echo sequence produced a gapless series of thin transverse sections (TE 9.2 ms, TR 21 ms, flip angle 30°, field of view 256 mm, acquisition matrix 256 × 256, slice thickness 1 mm). Then, for the next 6 patients, a 3-T MR scanner (Sigma HDx, General Electric) was used. 3D volumetric acquisition of a T1-weighted 3-dimensional fast spoiled gradient-recalled acquisition in the steady-state sequence produced a gapless series of thin transverse sections (TE 2.8 ms, TR 7.0 ms, flip angle 8°, field of view 260 mm, acquisition matrix 256 × 256, slice thickness 1 mm). Finally, for 1 patient and 10 controls, T1-weighted MR images were obtained with another 3-T MR scanner (MAGNETOM Verio, Siemens). 3D volumetric acquisition of a T1-weighted gradient echo sequence produced a gapless series of thin sagittal sections (TE 1.95 ms, TR 2300 ms, TI 900 ms, flip angle 9°, field of view 250 mm, acquisition matrix 256×256, slice thickness 1 mm).

Region of Interest (ROI) Definition {#s6}
-----------------------------------

All ROIs used in our analyses were initially defined on a standard anatomic orientation (MNI standard space; Montreal Neurological Institute). Striatum ROIs (caudate, putamen, and ventral striata) were defined using a striatum anatomical atlas ([@CIT0042]). A cerebellum ROI was defined with a probabilistic cerebellar atlas ([@CIT0007]), excluding the vermis.

These ROIs were transformed into individual MR spaces with transformation matrices calculated with the "normalize" function of statistical parametric mapping software (SPM12; Wellcome Department of Imaging Neuroscience) and were thresholded using FreeSurfer's automated anatomical segmentation ([@CIT0009]) to exclude neighboring white matter, ventricles, and non-brain regions. Time-activity curves for each ROI were extracted by applying these ROIs to individual dynamic PET images based on the transformation parameters for the coregistration of MR images to the PET spaces using PMOD software ver. 3.7 (PMOD Technologies Ltd).

Quantification of Total D2R and D2^High^ Availabilities in the Striatum {#s7}
-----------------------------------------------------------------------

Availabilities of striatal total D2R and D2^High^ were quantified as binding potentials relative to the nondisplaceable tissue (*BP*~ND~) of \[^11^C\]raclopride and \[^11^C\]MNPA, respectively. \[^11^C\]raclopride *BP*~ND~ and \[^11^C\]MNPA *BP*~ND~ were calculated for each ROI using a 3-parameter simplified reference tissue model ([@CIT0019]) and cerebellar cortex as reference tissue, which has negligible density of D2R ([@CIT0039]). *BP*~ND~ was defined as follows:
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where *f*~ND~ is the free fraction of radioligand in the nondisplaceable tissue compartment and *B*~avail~ indicates the neuroreceptor density. All kinetic analyses were performed using PMOD software ver. 3.7.

Statistical Analysis {#s8}
--------------------

Statistical analyses were conducted with SPSS 23.0 (SPSS Inc). First, MANCOVA was applied to examine group differences in: (1) *BP*~ND~ of \[^11^C\]raclopride; (2) *BP*~ND~ of \[^11^C\]MNPA; and (3) the *BP*~ND~ ratio (ratio of \[^11^C\]MNPA *BP*~ND~ to \[^11^C\]raclopride *BP*~ND~) in 3 striatal ROIs (caudate, putamen, and ventral striata), separately. A fixed factor was diagnosis (patients = 1, controls = 0). Nuisance covariates were defined as age, gender, and smoking state (smoker = 1, nonsmoker = 0) to control for their potential effects on D2Rs ([@CIT0047]; [@CIT0027]). Statistical significance threshold was defined as *P*\<.05 (2-tailed).

Second, correlational analyses were performed between the *BP*~ND~ values mentioned above and each of the PANSS factor scores (positive, negative, disorganized/concrete, excited, and depressed factors) in patients. The statistical threshold was set at *P*\<.05 with Bonferroni correction for the 3 striatal subregions (caudate, putamen, and ventral striata), as in previous studies ([@CIT0041]; [@CIT0027]). Because of the small sample size and exploratory nature of this study, corrections were not applied for multiple comparisons of the 5 PANSS factor scores and the 3 binding parameters (\[^11^C\]raclopride *BP*~ND~, \[^11^C\]MNPA *BP*~ND~, and their ratio). In case significant correlations were found, partial correlation analyses were also performed, controlling for age, gender, smoking state, or duration of illness. Statistical significance threshold was defined as *P*\<.05 (2-tailed).

Results {#s9}
=======

Demographic Data {#s10}
----------------

Demographic data are shown in [Table 1](#T1){ref-type="table"}. Patients and controls did not significantly differ in terms of age, gender, or proportion of smokers. Injected dose and specific radioactivity of \[^11^C\]raclopride and \[^11^C\]MNPA were not significantly different between the 2 groups.

Group Comparisons of Radioligand Binding {#s11}
----------------------------------------

Results of group comparisons of *BP*~ND~ values are shown in [Table 2](#T2){ref-type="table"} and [Figure 1](#F1){ref-type="fig"}. MANCOVA demonstrated a significant main effect of diagnosis on the *BP*~ND~ ratio (F = 4.16, *P*=.018), although the effects of diagnosis on *BP*~ND~ values obtained with either \[^11^C\]raclopride or \[^11^C\]MNPA were nonsignificant. Posthoc analysis by univariate test revealed a significant effect of diagnosis on the putaminal *BP*~ND~ ratio (F = 6.64, *P*=.017), indicating that the *BP*~ND~ ratio in the putamen of patients was significantly higher.

###### 

Comparisons of *BP*~ND~ of \[^11^C\]raclopride, *BP*~ND~ of \[^11^C\]MNPA, and *BP*~ND~ Ratio of \[^11^C\]MNPA to \[^11^C\]raclopride between the Patient and Control Groups

                                     Patient group (n=11)   Control group (n=17)   Multivariate tests   Between-subject effects (posthoc)                             
  ---------------------------------- ---------------------- ---------------------- -------------------- ----------------------------------- ------ ----------- ------ -----------
  *BP* ~ND~ of \[^11^C\]raclopride                                                                      1.50                                .24                       
  Caudate                            2.21                   0.34                   2.30                 0.35                                                          
  Putamen                            2.89                   0.36                   3.04                 0.31                                                          
  Ventral striatum                   1.98                   0.36                   2.12                 0.22                                                          
  *BP* ~ND~ of \[^11^C\]MNPA                                                                            2.48                                .09                       
  Caudate                            0.45                   0.10                   0.47                 0.11                                                          
  Putamen                            0.76                   0.06                   0.75                 0.07                                                          
  Ventral striatum                   0.49                   0.09                   0.54                 0.07                                                          
  *BP* ~ND~ ratio                                                                                                                           4.16   .018^*a*^          
  Caudate                            0.203                  0.020                  0.202                0.032                                                  0.11   .74
  Putamen                            0.265                  0.022                  0.249                0.020                                                  6.64   .017^*a*^
  Ventral striatum                   0.256                  0.054                  0.258                0.031                                                  0.00   .98

^*a*^ *P* \< .05.

![A group comparison of binding potential ratio (*BP*~ND~ ratio) (\[^11^C\](R)-2-CH3O-N-n-propylnorapomorphine (\[^11^C\]MNPA) to \[^11^C\]raclopride) in striatal subregions. A significant diagnostic effect was found on the *BP*~ND~ ratio (*P*=.018; MANCOVA controlled for age, gender, smoking). Univariate posthoc analysis showed that the *BP*~ND~ ratio in the putamen was significantly higher in patients (*P*=.017). HC, healthy control group; Pt, patient group.](pyx06301){#F1}

Because age distribution was reasonably matched between the 2 groups both numerically and statistically ([Table 1](#T1){ref-type="table"}), we repeated the analysis excluding age from nuisance covariates to confirm our results on the *BP*~ND~ ratio. This MANCOVA also showed a significant main effect of diagnosis on the *BP*~ND~ ratio (F = 3.68, *P*=.028). Univariate posthoc analysis revealed a significant effect of diagnosis on the putaminal *BP*~ND~ ratio (F = 5.83, *P*=.024), indicating that the *BP*~ND~ ratio, compared with that of controls, was significantly higher in the putamen of patients.

Correlation Analyses {#s12}
--------------------

Significant positive correlations were found between PANSS depressed factor and *BP*~ND~ of \[^11^C\]raclopride (Pearson's r = 0.773, *P*=.005) and of \[^11^C\]MNPA (r = 0.701, *P*=.016) in the caudate ([Figure 2](#F2){ref-type="fig"}). No other significant correlation was found. Partial correlations of PANSS depressed factor with the *BP*~ND~ of both \[^11^C\]raclopride and \[^11^C\]MNPA in the caudate were significant after controlling for age, gender, smoking state, or duration of illness.

![Scatter plots of binding potential (*BP*~ND~) values against Positive and Negative Syndrome Scale (PANSS) "depressed" factor and linear regressions in the caudate of patients with schizophrenia. PANSS "depressed" factor was significantly and positively correlated with *BP*~ND~ of \[^11^C\]raclopride (left: Pearson's r = 0.773, *P*=.005) and of \[^11^C\](R)-2-CH3O-N-n-propylnorapomorphine (\[^11^C\]MNPA) (right: r = 0.701, *P*=.016). Statistical significance threshold: *P*\<.05 for the 3 striatal subregions (Bonferroni correction).](pyx06302){#F2}

Discussion {#s13}
==========

The binding of \[^11^C\]raclopride and \[^11^C\]MNPA did not significantly differ between patients and controls. This is consistent with most of the previous D2/3 receptor studies using different radioligands, in which no clear differences were shown between the 2 diagnostic groups ([@CIT0041]; [@CIT0013]; [@CIT0015]; [@CIT0004]; [@CIT0040]). On the other hand, the current study revealed that the *BP*~ND~ ratio of \[^11^C\]MNPA to \[^11^C\]raclopride in the putamen was significantly higher in patients with schizophrenia.

In previous studies on animal models of schizophrenia, the proportion of D2^High^ in the striatum was markedly increased ([@CIT0032]; [@CIT0030]), while D2R density in this area was not significantly changed. Several different animal models of schizophrenia have been reported, such as amphetamine-sensitized rats, mice deficient in types 2 and 3 metabotropic glutamate receptors, trace amine 1 receptor knockout mice, and rats with a neonatal hippocampus lesion. Interestingly, dopamine super-sensitivity ([@CIT0020]) and marked increase in D2^High^ without significant increase in total D2Rs have been observed in most of these animal models ([@CIT0001]; [@CIT0032]; [@CIT0046]; [@CIT0029]; [@CIT0034]). These findings imply that there may be a variety of mechanisms that can lead to increases in D2^High^. As such, it appears that D2^High^ could be one of the common mechanisms of schizophrenia. Although molecular processes triggering this change are not clear, one explanation might be that the constant oscillation between the high- and low-affinity states of D2R is altered in schizophrenia, and the conversion rate of D2^High^ to D2^Low^ may be slower than a normal condition, resulting in an increase in the proportion of D2^High^ ([@CIT0031]). The extent of the group difference in the *BP*~ND~ ratio observed in our study was not as prominent as the increase in the proportion of D2^High^ shown in animal models of psychosis. This might be due to the difference between in vitro tissue assays and in vivo PET imaging ([@CIT0013]), and it is likely that a low-grade but long-lasting abnormality of D2^High^ over decades may lead to the onset of schizophrenia. There is also a possibility that the contribution of D2^High^ alterations vs other neurochemical factors to the etiology of schizophrenia might be variable among individuals in consideration of the heterogeneity of neuroreceptor statuses in subjects with this disease. The current work indicated a higher proportion of D2^High^ in the putamen of patients with schizophrenia, while it is yet to be elucidated how neurochemical and functional abnormalities in this striatal subregion contribute to the onset of the disease. MRI studies have documented involvements of putaminal volume changes in the evolution of a clinical high risk status for psychosis ([@CIT0002]) and worsening of clinical outcomes in schizophrenia ([@CIT0023]). Hence, mechanistic links between these morphological alterations and a dysregulated affinity state of D2R in the putamen may need to be investigated in subjects at clinical high risk and with schizophrenia by longitudinal PET and MRI assays.

For the D2R/D3R selectivity of radioligands, unlike \[^11^C\]PHNO, both \[^11^C\]raclopride and \[^11^C\]MNPA have similar affinities to D2R and D3R according to an in vitro study ([@CIT0038]). Because D2Rs are predominant and only low levels of D3R have been detected in the caudate and putamen by previous binding assays or postmortem studies ([@CIT0024]; [@CIT0033]), and \[^11^C\]MNPA has a higher affinity for D2^High^ than D2^Low^ ([@CIT0035]), the *BP*~ND~ ratio of \[^11^C\]MNPA to \[^11^C\]raclopride in these regions could reflect the proportion of D2^High^ relative to total D2Rs with minimal influence of the D3R status.

PANSS depressed factor was positively correlated with both *BP*~ND~ of \[^11^C\]raclopride and \[^11^C\]MNPA in the caudate. A previous PET study with \[^11^C\]raclopride has reported its elevated binding in the caudate and putamen in medication-free patients with depression compared with healthy subjects ([@CIT0022]), suggesting the possible involvement of dopaminergic neurotransmission in depression and depressed subjects. Our results might indicate specific associations between depressive symptoms in schizophrenia and D2R availability in the caudate, in a manner independent of its affinity states. Since *BP*~ND~ values of both antagonistic \[^11^C\]raclopride and agonistic \[^11^C\]MNPA were correlated with the depression score, densities of D2Rs rather than occupancy of D2R by endogenous dopamine may increase in association with a depressive state. This dopaminergic modulation might not efficiently compensate for the mood change, in light of somewhat limited therapeutic application of dopaminergic stimulants to depressive conditions ([@CIT0014]). Accordingly, further studies with a larger sample size will be needed to better understand the current observations and to confirm them on the basis of more rigorous statistical criteria.

Several technical limitations of the current study should be taken into account. First, the sample size is relatively small, and the demographic compositions of gender and smokers vs nonsmokers are not equal between the 2 groups numerically, if not statistically. In addition, a previous PET study in a healthy population reported that central striatal D2R/D3R availability was negatively correlated with recent and lifetime smoking, and also with nicotine dependence ([@CIT0027]). Another PET study reported a significant gender-by-smoking interaction on D2R/D3R availability in the caudate and putamen ([@CIT0003]). These findings provide a rationale for the inclusion of gender and smoking as covariates of no interest, but an expanded analysis of patients and controls with a larger sample size and minimal inter-group differences in these factors will be required for more robust proof of the current results. Second, the temporal sequence of PET scans with \[^11^C\]raclopride and \[^11^C\]MNPA differed among the subjects. However, the occupancy of D2R by these ligands was \<1% based on their injected mass doses, and the interval between the initiations of the first and second PET scans was longer than 120 minutes in all subjects. Hence, effects of the sequence of PET scans with the 2 ligands on quantitative data are considered negligible. Third, 3 different MRI devices were used to acquire anatomical information on the brains of the subjects. To minimize a possible confounding effect of MRI qualities on kinetic analyses, we used the standard MNI space to define ROIs, which were eventually transformed into individual PET spaces. Finally, we used only PANSS to evaluate symptoms in patients with schizophrenia. Using multiple scales to assess delusion, hallucination, depression, and other symptoms of schizophrenia would be more desirable.

In conclusion, the present study has provided in vivo clinical evidence that a modulated proportion of D2^High^ is implicated in the molecular etiology of schizophrenia. Relationships between depressive symptoms and D2R levels in schizophrenia patients have also been demonstrated by the consistent observations with 2 radioligands. The combined use of \[^11^C\]raclopride and \[^11^C\]MNPA validated here could be applied to a PET study on a larger scale to further clarify involvement of the dopaminergic statuses in schizophrenia as a molecular basis of symptomatic manifestations.

Funding {#s105}
=======

This work was supported in part by a Grant-in-Aid for Research Activity Start-up (15H06873 to M.K.) from the Japan Society for the Promotion of Science; and the Brain Mapping by Integrated Neurotechnologies for Disease Studies (Brain/MINDS) and the Strategic Research Program for Brain Sciences to T.S. from the Japan Agency for Medical Research and Development, AMED. These agencies had no further role in the study design, collection, analysis or interpretation of the data, writing of the manuscript, or in the decision to submit the manuscript for publication.

Statement of Interest {#s106}
=====================

None.

We thank Kazuko Suzuki and Shizuko Kawakami for their assistance as clinical coordinators, Hiromi Sano and Naoto Sato for their support with MRI scans, and the staff of the Department of Radiopharmaceutics Development for the radioligand synthesis.
